Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 16, 2021 07:00 ET | Source: Immunocore Limited

Immunocore announces key appointments to management and Board

PRESS RELEASE Immunocore announces key appointments to management and Board Ralph Torbay appointed Head of Commercial to spearhead the launch of tebentafusp Dr. Roy S. Herbst appointed as a...
February 09, 2021 16:05 ET | Source: Immunocore Limited

Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to Purchase Additional ADSs and $15.0 Million Concurrent Private Placement

PRESS RELEASE Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to Purchase Additional ADSs and $15.0...
February 04, 2021 22:07 ET | Source: Immunocore Limited

Immunocore Announces Pricing of Upsized Initial Public Offering

PRESS RELEASE Immunocore Announces Pricing of Upsized Initial Public Offering OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US – 4 February 2021 – Immunocore Holdings plc...
January 11, 2021 07:00 ET | Source: Immunocore Limited

Immunocore announces closing of $75.0 Million Series C round

PRESS RELEASE Immunocore announces closing of $75.0 Million Series C round Funding follows positive Phase 3 trial interim analysis data for tebentafusp in patients with metastatic uveal melanoma ...
December 03, 2020 06:01 ET | Source: Immunocore Limited

Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020

PRESS RELEASE Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3...
November 23, 2020 02:00 ET | Source: Immunocore Limited

Immunocore’s tebentafusp demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma

PRESS RELEASE Immunocore’s tebentafusp demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal...
August 27, 2020 07:00 ET | Source: Immunocore Limited

Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B

PRESS RELEASE Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B New preclinical...
August 27, 2020 02:00 ET | Source: Immunocore Limited

Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B

PRESS RELEASE Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B New preclinical...
May 26, 2020 07:00 ET | Source: Immunocore Limited

Immunocore announces dosing of first patient with fourth ImmTAC®

PRESS RELEASE Immunocore announces dosing of first patient with fourth ImmTAC® IMC-F106C studied for the treatment of advanced cancers that express PRAME (OXFORDSHIRE, England & CONSHOHOCKEN,...
May 06, 2020 07:00 ET | Source: Immunocore Limited

Immunocore appoints Brian Di Donato as Chief Financial Officer and Head of Strategy

PRESS RELEASE Immunocore appoints Brian Di Donato as Chief Financial Officer and Head of Strategy (OXFORD, England & CONSHOHOCKEN, Pa. & ROCKVILLE, Md., 6 May 2020) Immunocore, a...